Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00002
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
(123B9)2L2PTX
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer
|
|||||
| Structure |
|
|||||
| Peptide Name |
123B9
|
Peptide Info | ||||
| Receptor Name |
Ephrin type-A receptor 2 (EPHA2)
|
Receptor Info | ||||
| Drug Name |
Paclitaxel
|
Drug Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Antitriazole
|
Linker Info | ||||
| Peptide Modified Type |
The modification of binding with chemical macromolecules
|
|||||
| Modified Segment |
Lys-Gly-Lys-Gly
|
|||||
| Ternimal Modification |
N-terminal modification
|
|||||
| Formula |
C195H262Cl2F2N34O63
|
|||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight | 4199.318 | ||||
| Lipid-water partition coefficient (xlogp) | -6.7164 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 42 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 63 | |||||
| Rotatable Bond Count (rotbonds) | 123 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Number of Lung metastases nodules |
5
|
|||
| Administration Time | 2 weeks | ||||
| Administration Dosage | 24.5 mg/kg | ||||
| Description |
We observed the clear and significant (p < 0.0001) beneficial effects of the dimer drug on lung metastasis (Figure5A,B), with a reduction of the gross lung-metastasis count by more than 75% compared with those in the control and Abraxane groups.
|
||||
| In Vivo Model | BALB/c mice syngeneic breast-cancer metastasis model. | ||||
References